Symptomatic therapy in multiple sclerosis: Big pharma should do more – NO

Institute of Medicine (US) Board on Neuroscience and Behavioral Health. Summary of a Workshop on Research in Multiple Sclerosis April 5–6, 2001. Washington, DC: National Academies Press, 2001.

Bar-Or A Calabresi PA Arnold D . Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395–400.

Naismith RT Piccio L Lyons JA . Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010; 74: 1860–1867.

Chataway J Schuerer N Alsanousi A . Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383: 2213–2221.

Bourgeois FT Murthy S Mandl KD . Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010; 153: 158–166.